Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ahmad Mouhamad Wehbe"'
Autor:
Ahmad Mouhamad Wehbe, Seungwon Kim, Dwight E. Heron, Frank R. Miller, Athanassios Argiris, Malabika Sen, Sufi M. Thomas, Jennifer R. Grandis, Umamaheswar Duvvuri, Brian J Karlovits, David A. Clump, Julie E. Bauman, William E. Gooding
Publikováno v:
Cancer. 124:3881-3889
Background Cetuximab combined with radiation therapy (RT) is an evidence-based treatment for locally advanced head and neck squamous cell carcinoma (HNSCC); however, locoregional failure remains the primary cause of cancer-related death in this disea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6193e272ef579497cd1ec7e67b1d717b
https://doi.org/10.1002/cncr.31651
https://doi.org/10.1002/cncr.31651
Autor:
Jennifer R. Grandis, Dwight E. Heron, Seungwon Kim, D.A. Clump, Athanassios Argiris, Jonas T. Johnson, Frank R. Miller, Robert L. Ferris, Ahmad Mouhamad Wehbe, Umamaheswar Duvvuri, Julie E. Bauman, William E. Gooding, James Ohr, Brian J Karlovits
Publikováno v:
Journal of Clinical Oncology. 33:6074-6074
6074 Background: Epidermal growth factor receptor (EGFR) is a validated therapeutic target in HNC. The combination of C-IMRT is a standard for locally advanced HNC; however, failure of locoregional control (LRC) remains the primary cause of cancer-re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f6470737152a621beb3d8d21b95d5762
https://doi.org/10.1200/jco.2015.33.15_suppl.6074
https://doi.org/10.1200/jco.2015.33.15_suppl.6074
Publikováno v:
Journal of Clinical Oncology. 33:e22004-e22004
e22004 TITTLE: A Phase II Study of Induction Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A) in Patients With ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7f7ce52eea49196a2e7bc9d976393d7
https://doi.org/10.1200/jco.2015.33.15_suppl.e22004
https://doi.org/10.1200/jco.2015.33.15_suppl.e22004
Autor:
Daniel Morgensztern, D. Ross Camidge, Pier Paolo Scaglioni, Rachel Sorensen, Timothy F. Burns, Ariel Lopez-Chavez, Mitchell Keegan, Suresh S. Ramalingam, Ahmad Mouhamad Wehbe, David T. Weaver, David E. Gerber, Joanna Horobin, Ronan J. Kelly, David R. Spigel
Publikováno v:
Journal of Clinical Oncology. 32:TPS8126-TPS8126
TPS8126 Background: KRAS mutations have been associated with poor prognosis in NSCLC and resistance to epidermal growth factor (EGFR) tyrosine kinase inhibitors. FAK represents a therapeutic target...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74b0b6e956750372eb811dd8eb63ffde
https://doi.org/10.1200/jco.2014.32.15_suppl.tps8126
https://doi.org/10.1200/jco.2014.32.15_suppl.tps8126
Publikováno v:
Journal of Clinical Oncology. 31:9090-9090
9090 Background: With an increasing aging population and a growing number of people with organ transplant on immune suppression, patients presenting with locally advanced, unresectable and metastatic SCCS are on the rise. Options of therapy are limit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::19d1b23e0cb977c7c605c23b6569febf
https://doi.org/10.1200/jco.2013.31.15_suppl.9090
https://doi.org/10.1200/jco.2013.31.15_suppl.9090